The future of incretin-based therapies is bright
Patients who took semaglutide (a glucagon-like peptide-1 receptor agonist specifically formulated for weight loss) alongside bimagrumab (a medication that inhibits muscle loss) in one study saw greater reductions in fat mass while preserving, or even gaining, lean mass
Our team can discuss available options and help you understand current pricing and payment choices during your consultation
This includes hospital stays, surgeries, medications, and rehabilitation
50 A recent meta-analysis including thirteen RCTs has shown that semaglutide and tirzepatide treatment significantly increases GI side effects such as nausea, vomiting, diarrhea, and constipation in obese individuals without diabetes compared to control groups
Follow-up visits every one to three months should track weight trends, waist circumference, metabolic markers, and subjective appetite levels